Xceleron Announces Key Board and Executive Appointments
News Jul 21, 2011
XCELERON, has announced that Dr. David Roblin has been appointed to its Board of Directors in a non-Executive capacity and Dr. Stuart Best has joined the company as Senior Director Operations.
Dr. Roblin joins the Xceleron Board from Pfizer Global R&D where he was most recently Senior Vice President R&D, Research Head and Site Director. He has an outstanding track record of product innovation and leadership, bringing about business and technology changes to improve productivity in research and development. His experience crosses therapeutic areas within the spectrum of small and large molecule R&D.
Dr. Best joins Xceleron from Merck, Scotland where he was Head of Bioanalysis. Dr. Best’s career has been distinguished by his leadership in applying progressively sophisticated analytical technologies to this expanding and complex area of chemistry.
Prior to Merck, Dr Best developed his reputation as an authority in the use of mass spectrometry in bioanalysis at Charles River (Inveresk).
Xceleron CEO Michael Butler commented: “These two new additions to our team come at an exciting time for the Company. In the last two years Xceleron has more than doubled its ‘top 20’ pharmaceutical clients and is increasingly being asked to provide supporting data for critical events and regulatory submissions. David Roblin is a hugely valuable addition to our Board, he understands the nature of the challenge that large pharma companies face and will help us to continue to meet that need.
Stuart Best is a seasoned pharma manager with a deep understanding of pharmaceutical clients’ operational needs and recognized expertise in the application of novel analytical technologies in drug regulatory development.”
Dr Roblin commented, “This is a unique opportunity with Xceleron. The pharmaceutical industry urgently needs innovative solutions and Xceleron’s ability to increase R&D productivity is creating a lot of client interest. The crucial benefits that we enable are reduction in cycle time from lead optimization to Phase 1, reduced development costs in Phases 1 and 2 and a shift in attrition from Phase 2 to Phase 1, making success in Phase 2 more likely.”
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019